Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Insulin-Like Growth Factor 1 (IGF-1) is a neurotrophic polypeptide with crucial roles to play in Central Nervous System (CNS) growth, development and maturation. Following interrogation of the neurobiology underlying several neurodevelopmental disorders and Autism Spectrum Disorders (ASD), both recombinant IGF-1 (mecasermin) and related derivatives, such as (1-3)IGF-1, have emerged as potential therapeutic approaches. Clinical pilot studies and early reports have supported the safety/preliminary efficacy of IGF-1 and related compounds in the treatment of Rett Syndrome, with evidence mounting for its use in Phelan McDermid Syndrome and Fragile X Syndrome. In ASD, clinical trials are ongoing. Here, we review the role of IGF-1 in the molecular etiologies of these conditions in addition to the accumulating evidence from early clinical studies highlighting the possibility of IGF-1 and related compounds as potential treatments for these childhood-onset neurodevelopmental disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Christensen, D. L., Baio, J., Braun, K. V. N., Bilder, D., Charles, J., Constantino, J. N., Daniels, J., Durkin, M. S., Fitzgerald, R. T., Kurzius-Spencer, M., et al. (2016) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6503a1 · Cited by 1,964
RetractedSynaptic, transcriptional and chromatin genes disrupted in autism
Study, T. D., De Rubeis, S., Autism, H. M. C. F., UK10K Consortium, The Autism Sequencing Consortium, He, X., Goldberg, A. P., Poultney, C. S., Samocha, K., Ercument Cicek, A., et al. (2014) · Nature · doi:10.1038/nature13772 · Cited by 2,746 · cited 1×
“…demonstrates complex genetics, and whilst it is a genetically heterogenous disorder, evidence repeatedly implicates genes involved in synaptic development, function and activity-dependent plasticity by both common and rare variation (Wang et al., 2009; Hussman et al., 2011; De Rubeis et al., 2014).”
Maenner, M. J., Warren, Z., Williams, A. R., Amoakohene, E., Bakian, A. V., Bilder, D. A., Durkin, M. S., Fitzgerald, R. T., Furnier, S. M., Hughes, M. M., et al. (2023) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7202a1 · Cited by 2,706
MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., & Zoghbi, H. Y. (2008) · Science · doi:10.1126/science.1153252 · Cited by 1,823
Transport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354 · cited 1×
“Although studies in rats have shown that there is clear exchange of BDNF between the brain and the periphery (Pan et al., 1998) and viceversa (Poduslo and Curran, 1996), other studies have failed to raise BDNF in the brain to therapeutic levels, suggesting crossing through the blood-brain barrier…”
BackgroundThe Story of Rett Syndrome: From Clinic to Neurobiology
Chahrour, M., & Zoghbi, H. Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.10.001 · Cited by 1,265
Common genetic variants on 5p14.1 associate with autism spectrum disorders
Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., Salyakina, D., Imielinski, M., Bradfield, J. P., Sleiman, P. M. A., et al. (2009) · Nature · doi:10.1038/nature07999 · Cited by 989 · cited 1×
“…demonstrates complex genetics, and whilst it is a genetically heterogenous disorder, evidence repeatedly implicates genes involved in synaptic development, function and activity-dependent plasticity by both common and rare variation (Wang et al., 2009; Hussman et al., 2011; De Rubeis et al., 2014).”
BackgroundZhou, Z., Hong, E. J., Cohen, S., Zhao, W.-N., Ho, H.-Y. H., Schmidt, L., Chen, W. G., Lin, Y., Savner, E., Griffith, E. C., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.037 · Cited by 877 · cited 2×
“Another important aspect of IGF-1 physiology is its binding to IGF Binding Proteins (IGFBP), which regulate its bioavailability, localization and activity (Ocrant et al., 1990; Clemmons, 1998; Hwa et al., 1999; Firth and Baxter, 2002).”
BackgroundThe many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872 · cited 12×
“Thus, signaling by IGF-1 and its active tripeptide may demonstrate different effects in different CNS cell populations, adding further to the biological complexity of IGF-1 signaling.”
BackgroundInfluentialDani, V. S., Chang, Q., Maffei, A., Turrigiano, G. G., Jaenisch, R., & Nelson, S. B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506071102 · Cited by 639
The genetics of autistic disorders and its clinical relevance: a review of the literature
Freitag, C. M. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001896 · Cited by 638
Beck, K. D., Powell-Braxtont, L., Widmer, H.-R., Valverde, J., & Hefti, F. (1995) · Neuron · doi:10.1016/0896-6273(95)90216-3 · Cited by 636 · cited 2×
“IGF-1 acts on its glycoprotein receptor (IGF1R), a tyrosine kinase receptor, to activate canonical signaling pathways, including: (i) the PI3K (phosphatidylinositol-3 kinase)—AKT1 (serinethreonine-specific protein kinase)—FOXO (forkhead box protein O) and (ii) the RAS—MAPK (mitogen-activated…”
BackgroundPoduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614 · cited 1×
“Although studies in rats have shown that there is clear exchange of BDNF between the brain and the periphery (Pan et al., 1998) and viceversa (Poduslo and Curran, 1996), other studies have failed to raise BDNF in the brain to therapeutic levels, suggesting crossing through the blood-brain barrier…”
BackgroundPartial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593 · cited 4×
“In the present Mini-Review, we address the role of perturbed IGF-1 signaling and the therapeutic potential of IGF-1 and (1-3)IGF-1 in neurodevelopmental disorders such as Rett Syndrome (RTT), Fragile X Syndrome (FXS), Phelan McDermid Syndrome (PMDS) as well as broader Autism SpectrumDisorder (ASD).”
BackgroundInfluentialSelf-citationBozdagi, O., Sakurai, T., Papapetrou, D., Wang, X., Dickstein, D. L., Takahashi, N., Kajiwara, Y., Yang, M., Katz, A. M., Scattoni, M. L., et al. (2010) · Molecular Autism · doi:10.1186/2040-2392-1-15 · Cited by 584 · cited 1×
“Using mice deficient in Shank3, Bozdagi et al. found reduced amplitude of miniature excitatory postsynaptic currents (mEPSCs) in the hippocampus and impaired Long Term Potentiation (LTP), with only transient spine expansion present (Bozdagi et al., 2010).”
BackgroundThe disease progression of Mecp2 mutant mice is affected by the level of BDNF expression
Chang, Q., Khare, G., Dani, V., Nelson, S., & Jaenisch, R. (2006) · Neuron · doi:10.1016/j.neuron.2005.12.027 · Cited by 578 · cited 2×
“Another important aspect of IGF-1 physiology is its binding to IGF Binding Proteins (IGFBP), which regulate its bioavailability, localization and activity (Ocrant et al., 1990; Clemmons, 1998; Hwa et al., 1999; Firth and Baxter, 2002).”
BackgroundDing, Q., Vaynman, S., Akhavan, M., Ying, Z., & Gomez-Pinilla, F. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.084 · Cited by 555
SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients
Shcheglovitov, A., Shcheglovitova, O., Yazawa, M., Portmann, T., Shu, R., Sebastiano, V., Krawisz, A., Froehlich, W., Bernstein, J. A., Hallmayer, J. F., et al. (2013) · Nature · doi:10.1038/nature12618 · Cited by 470 · cited 3×
“Treatment of the SHANK3 deficient neurons with IGF-1 increased the amplitude and frequency of EPSCs, restored the amplitude of evoked AMPA and NMDAR EPSCs and restored NMDA receptor currents on application of NMDA (Shcheglovitov et al., 2013).”
BackgroundMethodInfluentialAltered proliferation and networks in neural cells derived from idiopathic autistic individuals
Marchetto, M. C., Belinson, H., Tian, Y., Freitas, B. C., Fu, C., Vadodaria, K. C., Beltrao-Braga, P. C., Trujillo, C. A., Mendes, A. P. D., Padmanabhan, K., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.95 · Cited by 466 · cited 3×
“In contrast, a larger study has demonstrated significantly higher levels of IGF-1 in children with autism (Marchetto et al., 2016).”
BackgroundResultThe 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)
Phelan, K., & McDermid, H. E. (2011) · Molecular Syndromology · doi:10.1159/000334260 · Cited by 460
Clinical manifestations and stages of rett syndrome
Hagberg, B. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10020 · Cited by 416
Åberg, N. D., Brywe, K. G., & Isgaard, J. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.22 · Cited by 387 · cited 1×
“…growth and maturation of the CNS and its synapses, roles which have been reviewed extensively elsewhere (Bach et al., 1991; Popken et al., 2004; Aberg et al., 2006; Llorens-Martín et al., 2009; Corvin et al., 2012; O’Kusky and Ye, 2012; Supeno et al., 2013; Huat et al., 2014; Dyer et al.,…”
BackgroundThe Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370 · cited 1×
“…mRNA binding protein, expressed in neuronal cell bodies and dendrites acts to regulate protein translation at the synapse, with important roles to play in activity-dependent plasticity (e.g., inhibition of translation triggered by mGluR1/5 in response to neuronal stimulation) (Bhakar et al., 2012).”
BackgroundDeng, P.-Y., Rotman, Z., Blundon, J. A., Cho, Y., Cui, J., Cavalli, V., Zakharenko, S. S., & Klyachko, V. A. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.018 · Cited by 354
Shank Expression Is Sufficient to Induce Functional Dendritic Spine Synapses in Aspiny Neurons
Roussignol, G., Ango, F., Romorini, S., Tu, J. C., Sala, C., Worley, P. F., Bockaert, J., & Fagni, L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4354-04.2005 · Cited by 293
Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome
Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., Mellios, N., Tropea, D., & Sur, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311685111 · Cited by 242 · cited 7×
“The first is increased glutamatergic transmission, as seen in various preclinical studies (Tropea et al., 2009; Corvin et al., 2012; Castro et al., 2014; Marchetto et al., 2016).”
BackgroundInfluentialSelf-citationHussman, J. P., Chung, R.-H., Griswold, A. J., Jaworski, J. M., Salyakina, D., Ma, D., Konidari, I., Whitehead, P. L., Vance, J. M., Martin, E. R., et al. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-1 · Cited by 231
Neuropathology of Rett syndrome
Armstrong, D. D. (2005) · Journal of Child Neurology · doi:10.1177/08830738050200082401 · Cited by 207
Bozdagi, O., Tavassoli, T., & Buxbaum, J. D. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-9 · Cited by 176
NMDA Receptor Regulation Prevents Regression of Visual Cortical Function in the Absence of Mecp2
Durand, S., Patrizi, A., Quast, K. B., Hachigian, L., Pavlyuk, R., Saxena, A., Carninci, P., Hensch, T. K., & Fagiolini, M. (2012) · Neuron · doi:10.1016/j.neuron.2012.12.004 · Cited by 172 · cited 2×
“Thus, signaling by IGF-1 and its active tripeptide may demonstrate different effects in different CNS cell populations, adding further to the biological complexity of IGF-1 signaling.”
BackgroundRett Syndrome: Crossing the Threshold to Clinical Translation
Katz, D. M., Bird, A., Coenraads, M., Gray, S. J., Menon, D. U., Philpot, B. D., & Tarquinio, D. C. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2015.12.008 · Cited by 150
Huat, T. J., Khan, A. A., Pati, S., Mustafa, Z., Abdullah, J. M., & Jaafar, H. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-91 · Cited by 129 · cited 2×
“…section of the journal Frontiers in Neuroscience Received: 07 July 2016 Accepted: 20 September 2016 Published: 30 September 2016 Citation: Vahdatpour C, Dyer AH and Tropea D (2016) Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders.”
BackgroundNNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome
Deacon, R. M. J., Glass, L., Snape, M., Hurley, M. J., Altimiras, F. J., Biekofsky, R. R., & Cogram, P. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8341-2 · Cited by 78 · cited 2×
“Improvement in hyperactivity and anxiety, learning and memory deficits was also observed (Deacon et al., 2015).”
BackgroundCorvin, A. P., Molinos, I., Little, G., Donohoe, G., Gill, M., Morris, D. W., & Tropea, D. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.05.029 · Cited by 57 · cited 7×
“In one report studying the effects of IGF-1 acting on its canonical pathways in neuronal and non-neuronal cells, IGF-1 was found to increase pAkt statining in neurons but not glial cells, whilst (1-3) IGF-1 increased staining in glial cells but not neurons (Corvin et al., 2012).”
BackgroundInfluentialSelf-citation
Cited by
Building Models of Brain Disorders with Three-Dimensional Organoids
Amin, N. D., & Paşca, S. P. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.007 · Cited by 312
“Neuropsychiatric diseases cause considerable morbidity and mortality (The Lancet Neurology, 2017; Vigo et al., 2016), and progress in developing safe and efficacious treatments has been limited by inherent difficulty investigating neurobiological processes occurring in the human brain.”
Insulin-Like Growth Factor 1: At the Crossroads of Brain Development and Aging
Wrigley, S., Arafa, D., & Tropea, D. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00014 · Cited by 258
Self-citationNeurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance
Bozzi, Y., Provenzano, G., & Casarosa, S. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13595 · Cited by 250
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
Araya, P., Kinning, K. T., Coughlan, C., Smith, K. P., Granrath, R. E., Enriquez-Estrada, B. A., Worek, K., Sullivan, K. D., Rachubinski, A. L., Wolter-Warmerdam, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111883 · Cited by 50
Linker, S. B., Mendes, A. P. D., & Marchetto, M. C. (2020) · Molecular Autism · doi:10.1186/s13229-020-00359-w · Cited by 31
Metadata
- Authors
- Vahdatpour, C., Dyer, A. H., & Tropea, D.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-09-30
- Volume
- 10
- Pages
- 450-450
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2524986111
- Cited by
- 76
- References
- 34
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.